101 related articles for article (PubMed ID: 2917663)
1. Histological grading of breast cancer; significance of grade on recurrence and mortality.
Hopton DS; Thorogood J; Clayden AD; MacKinnon D
Eur J Surg Oncol; 1989 Feb; 15(1):25-31. PubMed ID: 2917663
[TBL] [Abstract][Full Text] [Related]
2. Determinants of axillary recurrence after axillary lymph node dissection for invasive breast cancer.
Voogd AC; de Boer R; van der Sangen MJ; Roumen RM; Rutten HJ; Coebergh JW
Eur J Surg Oncol; 2001 Apr; 27(3):250-5. PubMed ID: 11373100
[TBL] [Abstract][Full Text] [Related]
3. Clinicopathological correlation between expression of PTHrP receptor and various prognostic factors in breast cancer without axillary lymph node metastasis.
Suzuki Y; Tokuda Y; Saito Y; Umemura S; Osamura RY
Tokai J Exp Clin Med; 2005 Jul; 30(2):127-32. PubMed ID: 16146204
[TBL] [Abstract][Full Text] [Related]
4. [Local relapse in young (< or = 40 years) women with breast cancer after mastectomy or breast conserving surgery: 15-year results].
Fodor J; Mózsa E; Zaka Z; Polgár C; Major T
Magy Onkol; 2005; 49(3):203, 205-8. PubMed ID: 16249814
[TBL] [Abstract][Full Text] [Related]
5. Survival after negative sentinel lymph node biopsy in breast cancer at least equivalent to after negative extensive axillary dissection.
Kuijt GP; van de Poll-Franse LV; Voogd AC; Nieuwenhuijzen GA; Roumen RM
Eur J Surg Oncol; 2007 Sep; 33(7):832-7. PubMed ID: 17197151
[TBL] [Abstract][Full Text] [Related]
6. LEA-135 expression: its association with a lower risk of recurrence and increased overall survival of patients with lymph node-positive primary invasive breast cancer.
Saha B; Zhang N; Naritoku WY; Tsao-Wei DD; Groshen SL; Carlsson G; Larsson L; Gustavsson B; Chaiwun B; Taylor CR; Imam SA
Anticancer Res; 2004; 24(4):2391-400. PubMed ID: 15330189
[TBL] [Abstract][Full Text] [Related]
7. The prognostic significance of the percentage of positive/dissected axillary lymph nodes in breast cancer recurrence and survival in patients with one to three positive axillary lymph nodes.
Truong PT; Berthelet E; Lee J; Kader HA; Olivotto IA
Cancer; 2005 May; 103(10):2006-14. PubMed ID: 15812825
[TBL] [Abstract][Full Text] [Related]
8. Safety and feasibility of breast conserving therapy in Indian women: two decades of experience at Tata Memorial Hospital.
Dinshaw KA; Sarin R; Budrukkar AN; Shrivastava SK; Deshpande DD; Chinoy RF; Badwe R; Hawaldar R
J Surg Oncol; 2006 Aug; 94(2):105-13. PubMed ID: 16847919
[TBL] [Abstract][Full Text] [Related]
9. Breast cancer and axillary nodal status.
Chin HW; Guerra JF
J Can Assoc Radiol; 1980 Sep; 31(3):187-9. PubMed ID: 7419548
[TBL] [Abstract][Full Text] [Related]
10. [Axillary lymph node recurrence after sentinel lymph node biopsy for breast cancer].
Mathelin C; Salvador S; Guyonnet JL
J Gynecol Obstet Biol Reprod (Paris); 2007 May; 36(3):253-9. PubMed ID: 17317037
[TBL] [Abstract][Full Text] [Related]
11. [Risk factors for the development of recurrences in patients with breast carcinoma without axillary lymph node metastases].
Akkersdijk WL; Pieters JH; Smits JG; de Kruif JT; van der Tweel I; de Graaf PW
Ned Tijdschr Geneeskd; 1993 Nov; 137(46):2391-5. PubMed ID: 8264825
[TBL] [Abstract][Full Text] [Related]
12. Management and outcomes of isolated axillary node recurrence in breast cancer.
Konkin DE; Tyldesley S; Kennecke H; Speers CH; Olivotto IA; Davis N
Arch Surg; 2006 Sep; 141(9):867-72; discussion 872-4. PubMed ID: 16983030
[TBL] [Abstract][Full Text] [Related]
13. Prognostic significance of residual breast disease and axillary node involvement for patients who had primary induction chemotherapy for advanced breast cancer.
Escobar PF; Patrick RJ; Rybicki LA; Hicks D; Weng DE; Crowe JP
Ann Surg Oncol; 2006 Jun; 13(6):783-7. PubMed ID: 16604475
[TBL] [Abstract][Full Text] [Related]
14. [Management of the axilla in breast cancer: evidences and unresolved issues].
Fodor J; Polgár C; Péley G; Németh G
Orv Hetil; 2001 Sep; 142(36):1941-50. PubMed ID: 11680099
[TBL] [Abstract][Full Text] [Related]
15. Treatment of 100 patients with sentinel node-negative breast cancer without further axillary dissection.
Roumen RM; Kuijt GP; Liem IH; van Beek MW
Br J Surg; 2001 Dec; 88(12):1639-43. PubMed ID: 11736979
[TBL] [Abstract][Full Text] [Related]
16. In lymph node-negative invasive breast carcinomas, specific chromosomal aberrations are strongly associated with high mitotic activity and predict outcome more accurately than grade, tumour diameter, and oestrogen receptor.
Janssen EA; Baak JP; Guervós MA; van Diest PJ; Jiwa M; Hermsen MA
J Pathol; 2003 Dec; 201(4):555-61. PubMed ID: 14648658
[TBL] [Abstract][Full Text] [Related]
17. Early distant relapse in "node-negative" breast cancer patients is not predicted by occult axillary lymph node metastases, but by the features of the primary tumour.
Colpaert C; Vermeulen P; Jeuris W; van Beest P; Goovaerts G; Weyler J; Van Dam P; Dirix L; Van Marck E
J Pathol; 2001 Apr; 193(4):442-9. PubMed ID: 11276002
[TBL] [Abstract][Full Text] [Related]
18. S-phase fraction determined on fine needle aspirates is an independent prognostic factor in breast cancer - a multivariate study of 770 patients.
Gazic B; Pizem J; Bracko M; Cufer T; Borstnar S; Pohar-Marinsek Z; Us-Krasovec M
Cytopathology; 2008 Oct; 19(5):294-302. PubMed ID: 18070112
[TBL] [Abstract][Full Text] [Related]
19. The significance of the site of recurrence to subsequent breast cancer survival.
Imkampe A; Bendall S; Bates T
Eur J Surg Oncol; 2007 May; 33(4):420-3. PubMed ID: 17049430
[TBL] [Abstract][Full Text] [Related]
20. Long-term prognosis of patients with axillary recurrence after axillary dissection for invasive breast cancer.
Voogd AC; Cranenbroek S; de Boer R; Roumen RM; Rutten HJ; van der Sangen MJ
Eur J Surg Oncol; 2005 Jun; 31(5):485-9. PubMed ID: 15922883
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
